NovaBridge's Givastomig is potentially a key factor in the company's re-rating. However, some reports suggest that despite rebranding and repackaging efforts, the company still carries significant risks. The company has also discussed clinical data and development plans for a separate treatment, VIS-101, for wet age-related macular degeneration.